Twist Bioscience Corp. Stock News

Twist Bioscience's growth continues to moderate, in part due to macro headwinds. While Twist's focus on transitioning to profitability in the near-term has significantly reduced cash burn, it has also taken much of the upside off the table. Twist's NGS business continues to be a growth driver, but much of this is already reflected in the share price.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth equity, today announced the appointment of Trynka Shineman Blake to its board of directors. She will also serve as a member of the audit committee. Ms. Shineman Blake most recently served as chief executive officer of Vistaprint, a Cimpress company, and brings nearly three decades of...

Twist Bioscience Corporation (NASDAQ:TWST ) Q3 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Adam Laponis - Chief Financial Officer Angela Bitting - Chief Corporate Responsibility Officer & Senior VP of Corporate Affairs Emily Marine Leproust - Co-Founder, Board Chair & CEO Patrick John Finn - President & COO Conference Call Participants Chad M. Wiatrowski - TD Co...

Twist Bioscience (TWST) Q3 Profit Surges

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth equity, today announced financial results and business highlights for the third quarter fiscal 2025 ended June 30, 2025. “A strong balance sheet and disciplined cost-management underpin our focused business execution,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Biosci...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced the launch of a humanized transgenic (HuTg) mouse model to expand and complement its offering of antibody discovery services and further streamline monoclonal antibody discovery. “The hum...

Cathie Wood's Ark funds have been really heating up in recent months. Perhaps her most intriguing and underrated fund is the Ark Genomics Revolution ETF (ARKG), which is packed full of extraordinary biotech innovators that could experience an AI tailwind like few other industries.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it has granted a total of 70,254 equity awards, consisting of 56,182 restricted stock units (“RSUs”) a...